Spend enough time in performance medicine or longevity circles, and you’ll hear the term “Class 2 peptides” come up with increasing frequency. But unlike formal pharmacological classifications, this isn’t a rigid or universally defined category. Instead, it’s a functional label: one that’s evolved within clinics and optimization-focused practices to describe a specific group of compounds.
In most modern contexts, “Class 2 peptides” refers to growth hormone–modulating peptides which are compounds that stimulate the body’s own production of growth hormone (GH), rather than replacing it outright. This distinction matters. Rather than acting as hormone replacement, these peptides work upstream, influencing the signaling pathways that regulate GH release and its downstream effects.
Within this framework, the category typically includes GHRH analogs, GHRPs (ghrelin receptor agonists), and several adjacent or downstream modulators. Together, they form the backbone of many peptide therapy protocols designed to influence body composition, recovery, and metabolic health.
What follows isn’t a definitive list but rather a commonly accepted core set used in performance and clinical settings.
The Foundation: GHRH Analogs
At the top of the hierarchy are growth hormone–releasing hormone (GHRH) analogs, which signal the pituitary gland to initiate GH release. Think of these as the “on switch” for the system.
CJC-1295 with DAC is one of the most widely used in this category. Its defining feature is longevity: with a half-life measured in days, it sustains elevated GH and IGF-1 levels over time, making it useful for protocols that prioritize consistency over precision.
Its counterpart, CJC-1295 without DAC (also known as Mod GRF 1-29), operates very differently. With a much shorter half-life, it mimics the body’s natural pulsatile rhythm of GH release, often making it a better fit for stacks that aim to preserve physiological patterns.
Earlier-generation compounds like Sermorelin still appear in some protocols, though they tend to produce milder effects and require more frequent dosing. Meanwhile, Tesamorelin stands apart as a more refined option, with clinical validation for reducing visceral fat and a more targeted mechanism of action.
The Amplifiers: GHRPs
If GHRH analogs initiate the signal, GHRPs amplify it.
These compounds act on the ghrelin receptor (GHS-R1a), increasing both the amplitude and frequency of GH release. In practice, they’re often paired with GHRH analogs to create a synergistic effect.
Ipamorelin is widely considered the most selective in this class. It stimulates GH release with minimal impact on cortisol or prolactin, making it a preferred choice in “clean” protocols.
More aggressive options like GHRP-2 and GHRP-6 deliver stronger GH pulses but come with trade-offs. Both can increase cortisol and prolactin levels, and GHRP-6 in particular is known for significantly increasing appetite: something that may be desirable in muscle-building contexts but counterproductive for fat loss.
At the far end of the spectrum is Hexarelin, one of the most potent GH secretagogues available. Its strength, however, comes with complexity, including potential receptor desensitization and emerging considerations around cardiovascular markers.
The Outlier: Oral GH Modulation
Not all compounds in this category are peptides in the strict sense, but some are grouped here based on function.
MK-677 (Ibutamoren) is the most notable example. As an oral ghrelin receptor agonist, it stimulates continuous GH and IGF-1 elevation rather than discrete pulses. This makes it uniquely convenient and uniquely impactful.
That impact, however, cuts both ways. Alongside increased growth signaling often comes increased hunger, water retention, and shifts in insulin sensitivity, making it a powerful but sometimes blunt tool.
The Extensions: Hybrid and Research Peptides
Beyond the core compounds are a handful of less common or more experimental peptides that still fall within the GH-modulation ecosystem.
Compounds like Examorelin (a variant related to Hexarelin) and Alexamorelin appear in more niche or research-oriented discussions. While they share mechanistic similarities with established GHRPs, they are less widely used and less thoroughly characterized in clinical settings.
Their inclusion in this category reflects the evolving nature of peptide therapy, where new compounds are continually being explored, even as the foundational stack remains relatively consistent.
Downstream Effects: The IGF-1 Axis
While many Class 2 peptides focus on stimulating GH release, others act further downstream.
IGF-1 LR3 and IGF-1 DES (1-3) bypass the upstream signaling entirely, delivering the effects of growth hormone at the tissue level. These compounds are associated with cellular growth, recovery, and muscle hypertrophy, with LR3 providing more systemic effects and DES offering more localized, short-acting activity.
Because they operate outside the body’s natural regulatory loop, they are often used more cautiously and typically in more advanced protocols.
The Specialist: HGH Fragment 176-191
Finally, there are peptides that sit adjacent to the GH axis but don’t behave like traditional growth modulators.
HGH Fragment 176-191 is one such compound. Rather than increasing GH or IGF-1 levels, it targets fat metabolism directly, promoting lipolysis without significantly influencing growth pathways. For that reason, it’s frequently included in fat loss-focused stacks.
How It All Works: A System, Not a Single Lever
What defines Class 2 peptides isn’t any one compound, but the system they collectively influence.
Some activate the GHRH receptor, initiating GH release. Others stimulate the ghrelin receptor, amplifying that signal. Still others act downstream, delivering the effects of GH at the tissue level.
In practice, these peptides are rarely used alone. They’re stacked strategically (for example, combining a GHRH analog like CJC-1295 with a GHRP like Ipamorelin) to mimic the body’s natural pulsatile secretion patterns, increase overall output, and avoid receptor fatigue.
A Category Defined by Practice, Not Textbooks
It’s worth emphasizing: there is no officially recognized “list of 14 Class 2 peptides” in medical literature. This classification is practice-driven, shaped by clinicians, researchers, and performance-focused communities rather than formal taxonomy.
What it represents is less a strict category and more a shared language: a way to group together compounds that influence one of the body’s most important regulatory systems.
And as peptide therapy continues to evolve, that language (and the list itself) will likely evolve with it.
From Theory to Practice: How Class 2 Peptides Are Actually Used
Understanding Class 2 peptides at a high level is one thing. How they’re actually deployed is another.
In performance medicine, these compounds are rarely prescribed in isolation. Instead, they’re combined into intentional stacks: structured protocols designed around a specific outcome. The same peptide might appear in multiple stacks, but its role shifts depending on dose, timing, and what it’s paired with.
At a systems level, every protocol is manipulating the same axis of growth hormone release, IGF-1 signaling, and downstream metabolic effects. What changes is the strategy.
Fat Loss: Precision Over Power
Fat loss protocols built around Class 2 peptides tend to prioritize control, not maximal output.
The goal isn’t to flood the body with growth hormone, but to optimize its timing and function, specifically to encourage fat mobilization while preserving lean tissue and metabolic stability.
This is where Tesamorelin often becomes the anchor. Backed by clinical data for reducing visceral fat, it provides a targeted approach that goes beyond surface-level weight loss. Paired with a selective secretagogue like Ipamorelin, the stack promotes clean, pulsatile GH release without significantly elevating cortisol or prolactin.
From there, some protocols introduce HGH Fragment 176-191, which operates almost like a specialist within the system: driving lipolysis directly without amplifying broader growth signals.
In this context, the most effective stacks are the ones that feel almost understated: subtle shifts in signaling that, over time, produce meaningful changes in body composition.
Muscle Gain: Turning Up the Signal
Muscle-building protocols take a more assertive approach. Here, the objective is clear: increase the amplitude and frequency of growth signaling to support hypertrophy, recovery, and performance.
The foundation typically starts with CJC-1295 with DAC, leveraging its long half-life to maintain elevated GH levels throughout the week. This is paired with a second signal (often Ipamorelin or the more potent GHRP-2) to intensify each release.
From there, stacks often extend downstream into the IGF-1 pathway. IGF-1 LR3 introduces a more systemic anabolic effect, enhancing protein synthesis and recovery across tissues, while IGF-1 DES is sometimes used more selectively for localized impact.
Then there’s MK-677, which shifts the paradigm entirely by maintaining continuous GH and IGF-1 elevation. It’s effective, but not without trade-offs: increased appetite, fluid retention, and changes in insulin sensitivity are common.
That tension is part of the design. Muscle-focused stacks are less about refinement and more about leveraging the full capacity of the system, accepting short-term inefficiencies in exchange for accelerated growth and recovery.
Cognitive Performance and Longevity: Restoring the Rhythm
The most nuanced use of Class 2 peptides isn’t about aesthetics, it’s about how the body functions over time.
Cognitive and longevity-focused protocols return to a simpler, more physiological approach. Instead of maximizing output, they aim to restore natural rhythms, particularly the relationship between growth hormone and sleep.
A common foundation is CJC-1295 without DAC paired with Ipamorelin. Together, they support pulsatile GH release that aligns more closely with the body’s endogenous patterns, especially during slow-wave sleep, when growth hormone plays a critical role in repair and recovery.
In some cases, low-dose MK-677 is introduced to deepen sleep cycles and enhance recovery, though its side effects require careful management. Tesamorelin may also appear in these stacks when metabolic health (particularly visceral fat) is part of the equation.
The defining characteristic here is restraint. Dosing is typically lower, protocols are often cyclical or intermittent, and the emphasis is on sustainability rather than intensity.
The outcome isn’t immediate transformation, but something more subtle: better sleep, clearer cognition, and improved recovery capacity over time.
One System, Three Strategies
What ties these approaches together is that they all operate on the same biological system but with entirely different intent.
-
Fat loss stacks refine the signal.
-
Muscle-building stacks amplify it.
-
Cognitive protocols regulate it.
And in each case, the effectiveness of the protocol depends less on the individual peptide and more on how the system is orchestrated as a whole.
Where This Is Headed
Peptide therapy is no longer a niche conversation. It’s part of a larger shift toward precision-based health optimization, where interventions are designed to influence specific pathways rather than relying on broad, generalized approaches.
Alongside GLP-1s, NAD+ therapies, and other emerging tools, Class 2 peptides represent a growing interest in working with the body’s signaling systems, not against them.
For now, these compounds occupy a unique position of bridging the gap between biology and intention, and redefining what it means to actively shape how the body performs, recovers, and ages.